AI Stocks Are Cracking—Is Wall Street's Next Gold Rush in Biotech?
Is Wall Street's AI boom running out of steam — or are investors overlooking an even bigger opportunity?On this episode of Wayve Wire, Wayve Capital CEO Joe Besecker and CIO Rhys Williams join host Todd M. Schoenberger, President and CEO of CrossCheck Media Inc., for a high-stakes discussion about Big Tech earnings, artificial intelligence, the Federal Reserve, and the investment opportunities emerging in life sciences.Alphabet's search business is showing signs of slowing. Microsoft is facing selling pressure despite results that impressed the Wayve Capital team. And investors are questioning whether the enormous cost of building AI infrastructure will deliver the returns Wall Street expects.But Joe Besecker sees something different developing.He believes life sciences and biotechnology could generate stronger investment returns than AI infrastructure over the next 12 to 18 months.From Eli Lilly and Merck to GLP-1 medications, personalized medicine, and AI-powered drug discovery, Joe explains why advances in healthcare could create an entirely new generation of investment opportunities.Rhys Williams weighs in on the AI trade, Google's changing search business, credit-market pressures, and why investors shouldn't abandon technology simply because another sector is gaining momentum.Inside this episode:Alphabet and the AI threat: Is artificial intelligence beginning to cannibalize Google's enormously profitable search business?Microsoft's earnings reaction: Why Rhys believes the market is punishing results that deserve a better reception.The next biotech boom: Joe's bullish outlook for Eli Lilly, Merck, and the broader life sciences industry.AI meets medicine: How artificial intelligence could accelerate drug discovery, personalized treatments, and pharmaceutical innovation.The Federal Reserve: Did Kevin Warsh make the right decision by holding interest rates steady?Credit-market warning signs: Why widening borrowing costs matter for AI infrastructure companies and private equity.America's debt problem: The growing challenge facing federal finances, Social Security, and future generations.Where investors look next: Why diversification, research, and identifying emerging trends may matter more than chasing yesterday's winners.The episode also features the Wayve Wire Sports Report, with a discussion of the World Series and the Breeders' Cup.The big question: Is AI still Wall Street's best investment opportunity — or could the next major wealth-creation cycle come from biotechnology?Watch Wayve Wire for institutional investment perspectives, market analysis, and candid conversations about the forces shaping Wall Street.Subscribe to CrossCheck Media and Biz Talk Today TV for more expert financial coverage.Wayve Wire is a Biz Talk Today TV production, part of CrossCheck Media Inc.#WayveWire #WallStreet #AIStocks #Biotech #StockMarket #WayveCapital #Investing #WayveWire, #WayveCapital, #JoeBesecker, #RhysWilliams, #ToddSchoenberger, #WallStreet, #StockMarket, #AIStocks, #ArtificialIntelligence, #BiotechStocks, #LifeSciences, #EliLilly, #GoogleStock, #MicrosoftStock, #FederalReserve, #KevinWarsh, #Investing, #MarketOutlook, #CrossCheckMedia, #BizTalkTodayTV📧 Contact on Email: [email protected] 📢 Disclaimer: The views and opinions expressed on this program are those of the hosts and guests and do not necessarily reflect the official policy or position of CrossCheck Media Inc., Biz Talk Today TV (BTT), or their affiliated entities and distribution partners. Content produced by CrossCheck Media across video, audio, and digital platforms is provided for informational and educational purposes only. Nothing presented should be construed as financial, investment, legal, tax, or gambling advice, nor as a recommendation to buy or sell any security, asset, wager, or strategy. All investments and wagers involve risk, including the possible loss of principal or money placed on a bet. Past performance and statistical analysis are not indic